Data-Driven Biomarker and Drug Discovery for Complex Disease

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 723

Special Issue Editors

Department of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
Interests: network pharmacology; metabolomics; machine learning; chemotherapy toxicity; Chinese medicine
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, China
Interests: cardiovascular disease; ion channel; post-translational modification
Center for Biotechnology, Anhui Agricultural University, Hefei 230036, China
Interests: mass spectrometry; natural products; antioxidation; diabetes; lipidomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Complex diseases, such as cardiovascular disorders, neurodegenerative conditions, and cancer, present formidable challenges to the medical community. These multifaceted ailments are not governed by single genetic factors or isolated environmental triggers. Instead, they arise from intricate interactions between genetic variations, environmental influences, and lifestyle factors. The era of big data, coupled with cutting-edge computational techniques, has revolutionized our ability to dissect the intricate landscape of complex diseases. The data-driven paradigm allows us to harness the wealth of information contained within diverse datasets, unravel intricate disease mechanisms, pinpoint novel biomarkers, and identify promising drugs.  This Special Issue serves as a platform for researchers to present innovative insights, methodologies, and discoveries that leverage extensive datasets in the quest for more effective solutions for complex disease. By leveraging vast datasets encompassing genomics, proteomics, metabolomics, clinical records, and other critical information, we aim to accelerate the translation of research findings into actionable solutions for patients. We invite contributions that elucidate the intricate web of factors underpinning complex diseases and offer potential biomarkers that can revolutionize diagnostics, prognostics, and treatment decisions. Moreover, we seek papers presenting novel drug targets and therapeutic compounds designed through data-driven insights. This Special Issue provides a platform to share your pioneering work, foster collaboration, and contribute to the advancement of healthcare. We welcome original research articles and reviews that resonate with the theme of data-driven biomarkers and drug discovery for complex diseases. We look forward to your submissions, anticipating that this Special Issue will inspire groundbreaking developments in the fight against complex diseases and bring us closer to effective medical interventions.

Dr. Yin Huang
Dr. Tao Ban
Dr. Huimin Guo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cardiovascular disease
  • diabetes
  • neurodegenerative diseases
  • genomics
  • proteomics
  • metabolomics
  • systems biology
  • data mining
  • biomarker
  • drug discovery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


27 pages, 6294 KiB  
Improved Immunotherapy Outcomes via Cuproptosis Upregulation of HLA-DRA Expression: Promoting the Aggregation of CD4+ and CD8+T Lymphocytes in Clear Cell Renal Cell Carcinoma
by Bowen Wang, Yiwen Liu, Feng Xiong and Chunyang Wang
Pharmaceuticals 2024, 17(6), 678; - 24 May 2024
Viewed by 321
Immunotherapy has shown promising clinical results in clear cell renal cell carcinoma (ccRCC), but low clinical target response rates due to dysfunction of the major histocompatibility complex (MHC) and an inhibitory tumor immune microenvironment (TIME) have largely limited the associated clinical benefits. In [...] Read more.
Immunotherapy has shown promising clinical results in clear cell renal cell carcinoma (ccRCC), but low clinical target response rates due to dysfunction of the major histocompatibility complex (MHC) and an inhibitory tumor immune microenvironment (TIME) have largely limited the associated clinical benefits. In the present study, we explored the feasibility of enhancing tumor-specific-MHC-II-HLA-DRA expression, counteracting the TIME’s suppressive effects, thereby improving the sensitivity of immune checkpoint inhibitor (ICI) therapy from the standpoint of cuproptosis. Immunohistochemical staining and in vitro experiments validated the expression of HLA-DRA in ccRCC and its positive impact on ICI therapy. Subsequently, we observed that cuproptosis upregulated HLA-DRA expression in a dose-dependent manner, further confirming the link between cuproptosis and HLA-DRA. In vivo experiments showed that cuproptosis increased the sensitivity to ICI treatment, and implementing cuproptosis alongside anti-PD-1 treatment curtailed tumor growth. Mechanistically, cuproptosis upregulates HLA-DRA expression at the transcriptional level in a dose-dependent manner by inducing the production of reactive oxygen species; high levels of HLA-DRA promote the expression of chemokines CCL5, CXCL9, and CXCL10 in the TIME, inhibiting the development of a pro-tumor microenvironment by promoting the infiltration of CD4+T and CD8+T cells, thereby synergizing ICI therapy and exerting anti-tumor effects. Taken together, this work highlights the role of cuproptosis in mediating TIME remodeling and synergistic immunotherapy, providing new evidence that cuproptosis can evoke effective anti-tumor immune responses. Full article
(This article belongs to the Special Issue Data-Driven Biomarker and Drug Discovery for Complex Disease)
Back to TopTop